title: Alterations in sperm motility after acute oral administration of sildenafil or tadalafil in young, infertile men.
abstract: OBJECTIVE
  To evaluate the acute effect of sildenafil and tadalafil on seminal parameters in young, infertile patients.
  
  
  METHODS
  Prospective, randomized, double-blind, crossover clinical investigation on semen parameters after the administration of a single dose of sildenafil (50 mg) or tadalafil (20 mg).
  
  
  METHODS
  An academic hospital as well as a male infertility center and clinical andrology laboratories.
  
  
  METHODS
  Eighteen young, infertile men.
  
  
  METHODS
  Oral administration of a single dose of sildenafil (50 mg) or tadalafil (20 mg) in a blind, randomized order. The semen samples were collected 1 or 2 hours after each treatment.
  
  
  METHODS
  Changes in sperm parameters after sildenafil and tadalafil administration, compared with the basal conditions.
  
  
  RESULTS
  A significant increase in sperm progressive motility (median value, 37.0% vs. 28.5%) was observed after sildenafil administration as compared with baseline; in contrast, a significant decreased value was observed after tadalafil (median value, 21.5% vs. 28.5%).
  
  
  CONCLUSIONS
  These preliminary results indicate that sperm motility appears to be acutely affected in young, infertile patients by a single dose of sildenafil and tadalafil, with opposite effects: stimulatory by the former and inhibitory by the latter.
authors.affiliation: Urology Unit, Azienda Ospedaliera Pisana, University of Pisa, Pisa, Italy. g.pomara@libero.it
authors.forename: Giorgio
authors.initials: G
authors.lastname: Pomara
authors.forename: Girolamo
authors.initials: G
authors.lastname: Morelli
authors.forename: Domenico
authors.initials: D
authors.lastname: Canale
authors.forename: Paolo
authors.initials: P
authors.lastname: Turchi
authors.forename: Carolina
authors.initials: C
authors.lastname: Caglieresi
authors.forename: Cecilia
authors.initials: C
authors.lastname: Moschini
authors.forename: Giovanni
authors.initials: G
authors.lastname: Liguori
authors.forename: Cesare
authors.initials: C
authors.lastname: Selli
authors.forename: Enrico
authors.initials: E
authors.lastname: Macchia
authors.forename: Enio
authors.initials: E
authors.lastname: Martino
authors.forename: Francesco
authors.initials: F
authors.lastname: Francesca
mesh_terms: D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000328:Adult; D002243:Carbolines / Q000494:pharmacology*; D018592:Cross-Over Studies; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D003864:Depression, Chemical; D004311:Double-Blind Method; D006801:Humans; D007248:Infertility, Male / Q000188:drug therapy*; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology*; D011687:Purines / Q000494:pharmacology; D000068677:Sildenafil Citrate; D013081:Sperm Motility / Q000187:drug effects*; D013268:Stimulation, Chemical; D013450:Sulfones / Q000494:pharmacology*; D000068581:Tadalafil
chemical_list: D002243:Carbolines; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068581:Tadalafil; D000068677:Sildenafil Citrate; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C406737:PDE11A protein, human; C517381:PDE5A protein, human